title: Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
abstract: BACKGROUND
  The authors conducted a pilot, randomized, open label with blind assessment, controlled trial to determine whether vitamin E supplementation has a neuroprotective effect in chemotherapy-induced peripheral nerve damage.
  
  
  METHODS
  Thirty-one patients with cancer treated with six courses of cumulative cisplatin, paclitaxel, or their combination regimens were randomly assigned in two groups and followed by neurologic examination and electrophysiologic study. Patients assigned in Group I (n = 16) received oral vitamin E at a daily dose of 600 mg/day during chemotherapy and 3 months after its cessation were compared to patients of Group II (n = 15), who received no supplementation and served as controls. The severity of neurotoxicity was summarized by means of a modified peripheral neuropathy score.
  
  
  RESULTS
  The incidence of neurotoxicity differed between the two groups, occurring in 4/16 (25%) patients assigned in the vitamin E supplementation group and in 11/15 (73.3%) patients assigned in the control group (p = 0.019). Mean peripheral neuropathy scores were 3.4 +/- 6.3 for patients of Group I and 11.5 +/- 10.6 for patients of Group II (p = 0.026). The relative risk (RR) of developing neurotoxicity was significantly higher in case of control patients, RR = 0.34, 95% CI = 0.14 to 0.84.
  
  
  CONCLUSIONS
  Vitamin E supplementation in cancer patients may have an important neuroprotective effect.
authors.affiliation: Neurology Department, University of Patras, Medical School, PO Box 1045, Rion, Patras, Greece. andargyriou@yahoo.gr
authors.forename: A A
authors.initials: AA
authors.lastname: Argyriou
authors.forename: E
authors.initials: E
authors.lastname: Chroni
authors.forename: A
authors.initials: A
authors.lastname: Koutras
authors.forename: J
authors.initials: J
authors.lastname: Ellul
authors.forename: S
authors.initials: S
authors.lastname: Papapetropoulos
authors.forename: G
authors.initials: G
authors.lastname: Katsoulas
authors.forename: G
authors.initials: G
authors.lastname: Iconomou
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000284:Administration, Oral; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D010865:Pilot Projects; D013736:Testicular Neoplasms / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014810:Vitamin E; D017239:Paclitaxel; D002945:Cisplatin